Psychotherapeutic Drugs

The advancements of psychotherapeutic drugs has enabled management of mental illness and other neurological problems in the general population, without requiring hospitalization. The success of these drugs in controlling symptoms has led to their widespread use in the vulnerable population of pregnant women as well, where the potential embryotoxicity of the drugs has to be weighed against the potential problems of the maternal neurological state. A thorough discussion of animal research and human clinical studies is used to determine the risk associated with the use of each drug category. The direction of future research using psychotherapeutic drugs should more closely parallel the methodology developed in the animal laboratories, especially since these models have already been used extremely successfully in specific instances in the investigation of neurotoxic agents.

  • Global Psychotherapeutic Drugs
  • Cannabis and Cannabinoids
  • Psychoactive Drugs
  • Placebo Medications
  • Current Trends in Psychotherapeutic Drugs
  • Effects of Psychotherapeutic Drugs and Mental Health
  • Therapeutic Drugs and Myths

Related Conference of Psychotherapeutic Drugs

April 11-12, 2024

4th Annual Congress on Mental Health

Amsterdam, Netherlands
May 23-24, 2024

41th Global Psychiatry and Mental Health Conference

Zurich, Switzerland
May 27-28, 2024

6th European Autism Congress

Paris, France
July 15-16, 2024

6th International Congress on Mental Health

Amsterdam, Netherlands
September 09-10, 2024

5th Annual Congress on Psychiatry

London, UK
September 09-10, 2024

9th International Conference on Addiction Therapy

Paris, France
October 21-22, 2024

18th International Conference on Mental Health & Psychiatry

Zurich, Switzerland
December 05-06, 2024

4th World Conference on Addiction Psychiatry

Prague,

Psychotherapeutic Drugs Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in